---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-064754"
form_type: "8-K"
ticker: "NNVC"
cik: "0001379006"
company_name: "NANOVIRICIDES, INC."
filed_at: "2026-05-21T10:01:46+00:00"
generated_at: "2026-05-21T10:09:21.793817+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "medium"
source: SEC EDGAR
---

# NanoViricides says NV-387 and NV-387-remdesivir expected to be effective against Ebola Bundibugyo strain in DRC

## Summary
- NV-387 is broad-spectrum antiviral entering Phase II for Mpox in DRC.
- NV-387-remdesivir is an oral formulation shown in animal models; PLOS ONE paper published.
- Encapsulation protects remdesivir from metabolism, improving efficacy per company.
- Company has a clinical site in DRC for Mpox; public health responders to decide on Ebola.
- Remdesivir was tested in prior Ebola trials but efficacy not established; antibodies approved only for Zaire strain.

## SEC filing metadata
- accession: 0001104659-26-064754
- form_type: 8-K
- ticker: NNVC
- cik: 0001379006
- company_name: NANOVIRICIDES, INC.
- filed_at: 2026-05-21T10:01:46+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: medium
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1379006/000110465926064754/0001104659-26-064754-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1379006/000110465926064754/tm2615268d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-064754
- JSON: https://secwatch.observer/filing/0001104659-26-064754.json
- Plain text: https://secwatch.observer/filing/0001104659-26-064754.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.